GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (NAS:VRTX) » Definitions » Accounts Payable

VRTX (Vertex Pharmaceuticals) Accounts Payable : $413 Mil (As of Dec. 2024)


View and export this data going back to 1991. Start your Free Trial

What is Vertex Pharmaceuticals Accounts Payable?

Vertex Pharmaceuticals's Accounts Payable for the quarter that ended in Dec. 2024 was $413 Mil.

Vertex Pharmaceuticals's quarterly Accounts Payable increased from Jun. 2024 ($328 Mil) to Sep. 2024 ($396 Mil) and increased from Sep. 2024 ($396 Mil) to Dec. 2024 ($413 Mil).

Vertex Pharmaceuticals's annual Accounts Payable increased from Dec. 2022 ($304 Mil) to Dec. 2023 ($365 Mil) and increased from Dec. 2023 ($365 Mil) to Dec. 2024 ($413 Mil).

Vertex Pharmaceuticals Accounts Payable Historical Data

The historical data trend for Vertex Pharmaceuticals's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Accounts Payable Chart

Vertex Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 155.10 195.00 303.90 364.90 413.00

Vertex Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 364.90 351.40 327.90 395.80 413.00

Vertex Pharmaceuticals Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Vertex Pharmaceuticals Accounts Payable Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Vertex Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (NAS:VRTX) » Definitions » Accounts Payable
Comparable Companies
REGN ALNY ONC BNTX SMMT INSM BMRN RPRX MRNA INCY ASX:CSL XKRX:207940 XBRU:ARGX XBRU:UCB XKRX:068270 HKSE:02269 XKRX:196170 OCSE:GMAB SHSE:603392 EXEL
Traded in Other Exchanges
VRTX:Mexico 1VRTX:Italy 0QZU:UK VX1:Germany VX1:Germany VX1:Germany VX1:Germany VRTX34:Brazil VRTX:Austria
Address
50 Northern Avenue, Boston, MA, USA, 02210
Website
https://www.vrtx.com
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Executives
David Altshuler officer: EVP, Global Research and CSO C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
Ourania Tatsis officer: EVP, Chief Reg. & Quality Off. C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Wagner Charles F Jr officer: EVP & Chief Financial Officer C/O MILLIPORE CORP, BILLERICA MA 01820
Atkinson Edward Morrow Iii officer: EVP, Chief Technical Ops. Off. C/O 89BIO, INC., 142 SANSOME STREET, SECOND FLOOR, SAN FRANCISCO CA 94104
Kristen Ambrose officer: SVP & Chief Accounting Officer C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON MA 02210
Jonathan Biller officer: EVP and Chief Legal Officer C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Reshma Kewalramani director, officer: CEO & President C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Jeffrey M Leiden director 15 N BEACH ROAD, HOBE SOUND FL 33455
Sangeeta N. Bhatia director C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Carmen Bozic officer: EVP and CMO C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Bruce I Sachs director C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Stuart A Arbuckle officer: EVP, COO VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST., CAMBRIDGE MA 02139
Amit Sachdev officer: SVP, Public Policy,Gov Affairs C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
Michel Lagarde director 450 LEXINGTON AVE., 31ST FLOOR, NEW YORK NY 10017
Terrence C Kearney director IN CARE OF HOSPIRA, INC., 275 NORTH FIELD DRIVE, LAKE FOREST IL 60045